Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (XETRA: BRM) is trading at €55.60, about ₹6,055 at today's EUR/INR rate, as of 30 Sep 2026, 5:00 AM ET, down 0.29% today. Indian residents can buy Bristol-Myers Squibb from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
€55.38
Today's high
€56.06
52 week low
€36.60
52 week high
€61.19
BRM opened at €55.38, closed previously at €55.76, and has traded between €36.60 and €61.19 over the past 52 weeks.
About
Bristol-Myers Squibb Company operates globally as a biopharmaceutical powerhouse, engaging in the research, development, licensing, manufacturing, and marketing of innovative health solutions. Its extensive product pipeline addresses critical conditions across various therapeutic areas, including hematology, oncology, cardiovascular health, immunology, fibrotic diseases, neuroscience, and COVID-19. Key offerings from the company include Revlimid, an oral immunomodulatory drug for treating multiple myeloma, and Eliquis, an oral inhibitor prescribed for reducing stroke risk in non-valvular atrial fibrillation and for managing deep vein thrombosis/pulmonary embolism. The anti-cancer therapy Opdivo is also part of its portfolio, alongside Pomalyst/Imnovid for multiple myeloma, and Orencia, used for adult patients with active rheumatoid arthritis and psoriatic arthritis. Other notable treatments comprise Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy product. Furthermore, the company provides Reblozyl for anemia in adult beta thalassemia patients, and Empliciti for multiple myeloma. More recent additions include Zeposia, targeting relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor for adult myelofibrosis; and Onureg, prescribed for adult acute myeloid leukemia. Bristol-Myers Squibb distributes its products through a wide network encompassing wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The firm, established in 1887 and formerly known as Bristol-Myers Company, is headquartered in New York, New York.
Key statistics
Avg. volume
1.46K
Market cap
€113.57B
P/E Ratio
13.85
Price-to-sales ratio
2.61
Enterprise value
$146.83B
Free cash flow yield
11.69%
Debt-to-equity ratio
1.93
Return on equity
38.18%
ROIC
16.42%
Beta
0.23
Dividend yield
3.99%
Last dividend
€2.16
Financial overview
Revenue
$48.20B
Earnings per share
$3.47
Free cash flow
$12.85B
Net profit margin
18.87%
Gross margin
70.16%
EBITDA
$19.24B
Revenue growth
-0.21%
Similar securities
This is not an investment recommendation
How to buy Bristol-Myers Squibb from India
Indian residents can buy Bristol-Myers Squibb shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to EUR.
Search for Bristol-Myers Squibb and place an order
Find Bristol-Myers Squibb by name or by its ticker, BRM, and choose an order type. Bristol-Myers Squibb trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Bristol-Myers Squibb position in EUR and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.
Read the full guide: how to invest in Bristol-Myers Squibb from India
Trading and taxes when buying Bristol-Myers Squibb from India
Trading and limits
- Trading hours
- 9:00 am – 5:30 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Bristol-Myers Squibb’s current yield is 3.99%.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Bristol-Myers Squibb stock?
Yes. Bristol-Myers Squibb (BRM) has been listed on XETRA since 1999, in the Drug Manufacturers - General industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to EUR. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Bristol-Myers Squibb share cost in rupees?
One Bristol-Myers Squibb share is €55.60 — about ₹6,055 at an EUR/INR rate of 108.91 on 29 Sep 2026. Both the Bristol-Myers Squibb price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Bristol-Myers Squibb from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Bristol-Myers Squibb shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the EUR/INR rate on the purchase and the sale date, so the rupee move counts alongside the Bristol-Myers Squibb price. Paasa issues a capital-gains statement for your return.
Does Bristol-Myers Squibb pay a dividend, and how is it taxed in India?
Yes. Bristol-Myers Squibb pays a dividend and the current yield is 3.99%; the last declared dividend was €2.16 per share, about ₹235.23. Dividends are taxed at your slab rate in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.
When can I trade Bristol-Myers Squibb from India?
XETRA trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Germany is on standard time. Orders can only execute during that window.
Is Bristol-Myers Squibb a Germany company, and does that change how it is taxed?
Bristol-Myers Squibb trades on XETRA in EUR, but the company is domiciled in United States. Bristol-Myers Squibb trades as an ordinary share listed directly in Germany, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Bristol-Myers Squibb shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Bristol-Myers Squibb holding, its cost and its closing value.
How do I sell Bristol-Myers Squibb and bring the money back to India?
You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in EUR in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Bristol-Myers Squibb?
Yes. Bristol-Myers Squibb is priced in EUR, so your rupee outcome combines the EUR move with the EUR/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.